Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Reinhild Bücheler a Division of Clinical
Pharmacology, University Hospital Tübingen, D-72076 Tübingen,
Germany, b Dr Margarete Fischer-Bosch Institut für Klinische
Pharmakologie, D-70376 Stuttgart, Germany, c Medizinischer Dienst der Krankenversicherung
Baden-Württemberg, D-77933 Lahr, Germany, d Wissenschaftliches Institut der AOK (Allgemeine
Ortskrankenkasse), D-53177 Bonn, Germany Correspondence
to: C H Gleiter christoph.gleiter@med.uni-tuebingen.de
| The first 150 words of the full text of this article appear below. |
Between 35% and 90% of the drugs prescribed to
hospitalised children are either not licensed for children's use or
are prescribed outside the terms of their product licence (off label
prescribing).
1 2
Subsequent adverse reactions are more
likely than with licensed products (6.0% v
3.9%).3 We analysed the extent of prescribing off
labelled products in a representative cohort of children in primary care.
| |
Patients, methods, and results |
|---|
We used the electronic database of prescriptions of Allgemeine
Ortskrankenkasse, Baden-Württemberg. This health insurer
covers more than four million people, 42% of the total population of the state. We retrospectively reviewed 1.74 million anonymous prescriptions written by 6886 office based doctors
specialists in
paediatric, general, or internal medicine
between 1 January and 31 March 1999 for 455 661 patients aged 0-16 years.
| Table Removed (Available Only in the Full Text) |
Each prescription was represented by a numerical code, describing the
drug's brand name, generic name, formulation, and content per dose
unit. Our database did not contain diagnoses, dosage recommendations,
or individually prepared
Read all Rapid Responses